![]() |
|
|
Vol. 56, Issue 6, 1105-1115, December 1999
Istituto di Biologia Cellulare, "Campus Adriano Buzzati-Traverso" Consiglio Nazionale delle Ricerche, Rome, Italy (P.F., J.F.A., A.S., R.H.B., P.B.); and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee (M.-A.B.)
| |
Summary |
|---|
|
|
|---|
DNA topoisomerase I (Top1p) relaxes supercoiled DNA by the formation of a covalent intermediate in which the active site tyrosine is transiently bound to the severed DNA strand. The antineoplastic agent camptothecin (Cpt) specifically targets Top1p and several mutations have been isolated that render the enzyme Cpt resistant. The mutated residues, although located in different regions of the enzyme, may constitute part of the Cpt binding site. To begin identifying the structural features of DNA Top1p important for Cpt-induced cytotoxicity, we developed a novel yeast genetic screen to isolate catalytically active, yet Cpt-resistant enzymes from a pool of human top1 mutants. Among the mutations isolated were substitutions of Ser or Val for Gly363, which like the Gly363 to Cys mutation previously reported by us, suppressed the Cpt sensitivity of Top1p. In contrast, each amino-acid substitution differed in its ability to suppress the lethal phenotype and catalytic activity of a human top1 mutant top1T718A that resembles Cpt by stabilizing the covalent intermediate. Biochemical analyses and molecular modeling support a model where interactions between two conserved domains, a central "lip" region containing residue Gly363 and the residues around the active site tyrosine (Tyr723), directly affect the formation of the Cpt-binding site and enzyme catalysis.
| |
Introduction |
|---|
|
|
|---|
DNA
topoisomerase I (Top1p) catalyzes the relaxation of supercoiled DNA
through the transient cleavage of one strand of a DNA duplex and is
fundamental to processes such as replication, recombination, and
transcription (Hsiang et al., 1985
; Chen and Liu, 1994
; Wang, 1996
;
Nitiss, 1998
). Eukaryotic Top1p is the cellular target of the antitumor
drug camptothecin (Cpt), which reversibly stabilizes the cleavable
complex, an intermediate in the enzyme's catalytic cycle (Hsiang et
al., 1985
; Chen and Liu, 1994
; Pommier et al., 1998
). Genetic and
biochemical studies have led to the identification of amino-acid
substitutions in Top1p that render the enzyme resistant to Cpt.
Mutations that yield catalytically active, yet drug-resistant enzymes
are clustered in highly conserved regions, which are themselves widely
separated along the linear amino-acid sequence of the protein. One
region surrounds the active site tyrosine, where several such mutations have been identified (Knab et al., 1993
, 1995
; Fujimori et al., 1995
;
Wang, 1997
). Another is located around residue 363 (Gly363) of
the human enzyme, where two mutations have been independently mapped
(Benedetti et al., 1993
; Rubin et al., 1994
). Collectively, these data
led to the working hypothesis that the Cpt-binding site is formed by a
cleft that contains DNA and residues responsible for Cpt resistance.
Recently, the three-dimensional structures of a 26-kDa fragment of
yeast DNA Top1p (yTop1p) (Lue et al., 1995
) and of reconstituted and
N-terminal truncated versions of human DNA Top1p (hTop1p) in complexes
with a 22-base pair DNA molecule (Redinbo et al., 1998
; Stewart et al.,
1998
) have been solved. The enzyme is organized in multiple domains
that "clamp" around the DNA molecule. DNA relaxation has been
proposed to proceed via "controlled rotation" in which the
covalently bound enzyme holds one end of the DNA duplex, and allows the
end downstream of the cleavage site to rotate around the remaining
phosphodiester bond (Redinbo et al., 1998
). The residues mutated in the
Cpt-resistant mutants are positioned in regions of the enzyme engaged
in DNA-protein interactions and are clustered along one face of the DNA
molecule. In hTop1p, Gly363 lies within a loop structure that
constitutes one of two "lips" that interact with the DNA and each
other in the closed DNA bound protein clamp (Redinbo et al., 1998
). The
corresponding structure of the 26-kDa yTop1p fragment, called the Cpt
loop, also contains this residue (Gly295) (Lue et al., 1995
). Lue et
al. (1995)
suggested that the Cpt loop was opposite the active site
tyrosine domain of the protein and formed a catalytic cleft. Indeed,
the close proximity of these domains is borne out in the cocrystals of
the reconstituted central and C-terminal fragments of hTop1p with DNA
(Redinbo et al., 1998
).
We describe a novel genetic screen to identify additional mutations
that suppress the Cpt sensitivity of hTop1p without abolishing catalytic activity. Among the mutants isolated were additional substitutions of Gly363. Substitution of Ser or Val for Gly363, in
mutants htop1G363S and htop1G363V, respectively, abolished the Cpt
sensitivity of these mutant proteins with only marginal effects on
enzyme activity. This was in contrast to the more than 100-fold
reduction in specific activity seen in the corresponding yeast top1
mutant Top1G295Vp (Hann et al., 1998b
). To address this apparent
discrepancy in the activities of identical amino-acid substituents in
hTop1p and yTop1p, despite the conservation of amino-acid sequence and
structure in this domain, we further investigated the effects of these
Gly363 substitutions in suppressing the lethal phenotype of a Top1
mutant that mimics Cpt. Herein, we show that substitution of Thr718 to
Ala in hTop1p mirrors the alterations in catalytic activity observed
with the same substitution in yTop1T722Ap, both in vitro and in vivo
(Megonigal et al., 1997
; Hann et al., 1998a
,b
) Moreover, we show that
the Cpt-resistant mutations at Gly363 have widely varied affects in
suppressing the lethal phenotype and catalytic activity of the
hTop1T718A mutant enzyme. Furthermore, molecular models were created
for the mutants, based on the three-dimensional structure of the human
enzyme. Along with biochemical analyses, these data suggest that
distinct interactions between the two conserved lip domains mediate the
Cpt sensitivity and catalytic activity of wild-type DNA Top1p. The
implications of this intramolecular suppression are discussed in the
context of current structural models for eukaryotic DNA Top1p.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials, Yeast Strains, and Plasmids.
Cpt (Sigma Chemical
Co., St. Louis, MO) was dissolved in dimethyl sulfoxide (DMSO) at 4 mg/ml. Saccharomyces cerevisiae strains EKY2
(MATa, ura3-52, his3
200,
leu2
1, trp1
63,
top1::HIS3) and JN2-134 (MATa,
rad52::LEU2, trp1, ade2-1,
his7, ura3-52, ise1, top-1,
leu2) were described previously (Bjornsti et al., 1989
; Kauh
and Bjornsti, 1995
). Strain JCW28 (Mata,
ura3-52, his3
200, leu2
1,
trp1
63, top2-4, top1
) was kindly
provided by Dr. J. C. Wang, Harvard University.
YCpGAL1-hTOP1 and ptac-hTOP1 have been described
(Bjornsti and Wang, 1987
; Bjornsti et al., 1989
). YEptopA-pGPD was
reported previously (Giaever and Wang, 1988
). pBlueAK3-1 DNA contains a
high-affinity DNA Top1p cleavage site (Knab et al., 1995
).
Cell Viability Assays
Top1
yeast strains were transformed with the YCpGAL1-hTOP1 constructs by
LiOAc treatment and selected on synthetic complete (SC)-uracil plus 2%
dextrose. Transformants were grown to an A595 = 0.5 and 5-µl aliquots of serial 10-fold dilutions were spotted onto
SC-uracil plates plus 2% dextrose or 2% galactose. Alternatively, cultures were diluted 1:100 into SC-uracil media containing 2% raffinose and, at an A595 = 0.3, induced with a final 2% galactose. At various time points, aliquots
were serially diluted and plated onto SC-uracil, 2%dextrose. The
number of colonies was counted following incubation at 30°C.
DNA Top1p Activity In Vivo.
Yeast strain JCW28 (top1
,
top2-4ts) was cotransformed with plasmid YEptopA-pGPD, which
constitutively expresses the bacterial topA gene (Giaever
and Wang, 1988
), and either YCpGAL1, YCpGAL1-hTOP1, or
YCpGAL1-htop1T718A. Transformants were grown at 25°C, a permissive temperature for the top2-4ts mutant, in SC-uracil-leucine plus dextrose. At A595 = 1.0, Top1p expression
was induced with 2% galactose. After 5 h, half of the culture was
shifted to 37°C for 3 h to inactivate DNA Top II. The cells were
harvested and disrupted as described (Worland and Wang, 1989
;
Gartenberg and Wang, 1992
) and the linking number distributions of
purified plasmid DNAs were determined by two-dimensional gel
electrophoresis (Benedetti et al., 1993
; Megonigal et al., 1997
). DNA
was transferred to a nylon membrane (Amersham Corp.) and probed for
2-µm plasmid sequences with a 32P-labeled
fragment prepared by random priming (Pharmacia, Piscataway, NJ).
Phosphoimager analysis was used to establish the ratio between positive
supercoils and relaxed DNA in each sample.
Purification of Mutant hTop1p.
Partial purification of DNA
Top1ps from galactose-induced EKY2 cells was achieved by
phosphocellulose column chromatography as described (Benedetti et al.,
1993
; Knab et al., 1995
). Coomassie-stained SDS-polyacrylimide gel
electrophoresis gels indicate the purity of these enzymes to be ~50
to 60%. Alternatively, a one-step purification was achieved with the
FLAG system (Kodak) as follows: sequences encoding the epitope DYKDDDY
were inserted at the 5' end of hTOP1 by polymerase chain
reaction. The tagged heTOP1 gene was sublconed into YCpGAL1
to produce YCpGAL1-heTOP1. Western blot and immunfluorescence analyses
verified that full-length heTop1p was recognized by the epitope-specific monoclonal antibody M2 (data not shown). To purify heTop1p, strain EKY2 was transformed with YCPGAL1-heTOP1 or
YCpGAL1-hetop1T718A, grown in SC-uracil plus dextrose and diluted 1:100
in SC-uracil plus raffinose. At an
A595 = 1.0, the cells were induced with 2%
galactose for 6 h. Cells were harvested by centrifugation, washed
with TEEG (TRIS, EDTA, EGTA, glycerol) buffer (50 mM Tris, pH 7.4, 1 mM
EDTA, 1 mM ethylene glycol bis(
-aminoethyl
ether)-N,N,N',N'-tetraacetic acid, 10% (v/v) glycerol, 100 µg/ml phenylmethylsulfonyl fluoride, 800 µg/ml
NaHSO3, 20 µg/ml benzamidine, 2 µg/ml
pepstatin A, 2 µg/ml leupeptin) and resuspended in TEEG buffer at 2 ml buffer/g cells (wet weight). Then 0.5 volumes of 0.5-mm glass beads
were added, and the cells were disrupted with ten 30-s cycles of
vortexing alternating with 30 s on ice. The lysate was clarified
by centrifugation and incubated for 1 h at 4°C with the M2
antibody covalently coupled to an insoluble resin (Kodak). The resin
was washed three times for 10 min with 10 mM Tris, pH 7.4, 150 mM NaCl,
0.05% Tween 20, and used directly in activity or cleavage assays.
DNA Top1p Activity In Vitro.
DNA Top1p activity was assayed
in DNA relaxation reactions (Bjornsti and Wang, 1987
; Bjornsti et al.,
1989
). Briefly, DNA Top1p preparations were incubated in 30-µl
reaction volumes containing 0.5 µg of negatively supercoiled plasmid
pHC624 DNA and reaction buffer [20 mM TRIS (pH 7.5), 0.1 mM
Na2EDTA, 10 mM MgCl2, 50 µg/ml acetylated BSA, and 100 mM KCl]. After 1 h at 37°C, the
reaction products were analyzed in 1% agarose gels. One unit of
activity was the amount of enzyme needed to completely relax 0.5 µg
of negatively supercoiled plasmid under standard reaction conditions. To assess the effects of Cpt on enzyme activity, 50 µM Cpt was added
to the reactions and the extent of plasmid DNA relaxation at 0.5, 1, 5, 15, and 30 min was determined with a Bio-Rad GS 700 imaging
densitometer with Multi Analyst software.
DNA Cleavage Assays.
As described (Benedetti et al., 1993
;
Knab et al., 1995
; Megonigal et al., 1997
), cleavage of DNA by DNA
Top1p was assayed by incubating enzyme preparations or
immunotag-purified enzymes with a double-stranded DNA fragment,
radiolabeled at one unique 3' end, in the presence or absence of
camptothecin. A 900-base pair DNA fragment containing a high affinity
DNA Top1p cleavage site (Bonven et al., 1985
) was single
32P-end labeled and purified from plasmid
pBlueAK3-1 as described (Knab et al., 1995
). Enzyme preparations were
incubated in 50-µl reactions with DNA, reaction buffer and, where
indicated, 100 µM camptothecin. DMSO was added to the no-drug
controls. Following incubation at 37°C for 1, 5, or 30 min, reactions
were terminated by the addition of 1% SDS, heated to 75°C for 15 min, and treated with 0.2 µg/ml proteinase K. The cleaved DNA
fragments were resolved in 8 M urea/8% polyacrylamide gels and
visualized by autoradiography (Benedetti et al., 1993
; Knab et al.,
1995
)
Fluorescence Microscopy EKY2 cells, transformed with YCpGAL1-htop1T718A and induced with galactose for 6 h, were fixed by the addition of a final 3.7% formaldehyde. After 30 min, cells were pelleted and resuspended in 100 mM KPO4, pH 7.0, and 3.7% formaldehyde. After 30 min, the fixed cells were washed three times with 100 mM KPO4, sonicated, and stored at 4°C. To visualize nuclei, cells were resuspended in mounting medium (10 mM NaPO4 pH 7, 150 mM NaCl, 90% glycerol, 1 µg/ml p-phenylenediamine) plus 1.0 µg/ml 4,6-diamidino-2-phenylindole and viewed in a Leitz Axioplan microscope equipped with a UV filter set. Large-budded cells (defined as cells in which the bud was at least one-half as large as the mother cell) were scored for the presence of a single nucleus, two nuclei, or one nucleus in the bud neck. One hundred cells were scored for each of five experiments, by an observer blinded to the identity of the samples.
Molecular Simulations.
Models of enzyme mutants were
constructed based on the coordinates of hTop1p (70 kDa) in noncovalent
complex with a 22-base pair DNA duplex (Redinbo et al., 1998
; Stewart
et al., 1998
). Hydrogens were added and the whole structure
energy-minimized. Appropriate amino-acid substitutions were made and
each structure was energy-minimized with only residues within a
20Å-radius from each mutation free to move. The programs Insight II,
Biopolymer, and Discover (Molecular Simulations, Inc., Sunnyvale, CA)
were used for viewing and creating the models. Minimizations were
performed with the AMBER all-atom forcefield (Weiner, 1981
; Weiner et
al., 1984
), a distance-dependent dielectric constant (4xR) and the conjugate gradients algorithm to final maximum derivative of 0.01 kcal/A.
| |
Results |
|---|
|
|
|---|
Yeast Genetic Screen for Catalytically Active, Cpt-Resistant hTop1
Mutants.
Previously, we examined DNA Top1 mutants in yeast (for
review, see Bjornsti et al., 1994
; Benedetti et al., 1998
; Reid et al.,
1998
) and showed that cytotoxicity requires the presence of an active
enzyme because top1
yeast lacking DNA Top1 are Cpt resistant. A large percentage of Cpt-resistant top1
yeast
cells tranformed with a mutagenized pool of hTOP1 will
express enzymes with reduced catalytic activity. To avoid brute-force
screening of the subset of catalytically active, Cpt-resistant htop1
mutants, a genetic screen was devised that took advantage of the fact
that yeast strains deficient in DNA repair (due to deletion of the RAD52 gene) tolerate only limited amounts of
hTOP1. JN2-134 (rad52
) cells tolerate
pGAL1-promoted hTOP1 expression from a single
copy vector, but exhibit decreased viability when the enzyme is
expressed from pGAL1 on a multicopy vector (Bjornsti et al.,
1989
). Yet, leaky expression from this same multicopy YEpGAL1-hTOP1
vector is sufficient to render JN2-134 cells sensitive to 5 to 10 µg/ml Cpt on dextrose plates. Thus, catalytically active,
Cpt-resistant htop1 mutants may be selected by replica
plating Cpt-resistant colonies onto galactose plates and identifying
the inviable cells (Fig. 1).
|
) cells, colonies
grown on dextrose Cpt plates were replica plated onto galactose plates
to score catalytically active, Cpt-resistant htop1 mutants.
Selected colonies were assesed for hTop1p catalytic activity plasmid
DNA relaxation assays. YEpGAL1-htop1 plasmid DNA was recovered (Robzyk
and Kassir, 1992hTop1G363Sp and hTop1G363Vp Are Cpt Resistant.
htop1G363S and htop1G363V were cloned into the
single copy vector YCpGAL1-hTOP1 to assess Cpt sensitivity in repair
proficient EKY2 cells. As reported for htop1G363C, where
Gly363 is mutated to Cys (Benedetti et al., 1993
), cells expressing
htop1G363S and htop1G363V were resistant to high
doses of Cpt (5 µg/ml) (Fig. 2A).
|
hTop1T718A Is Lethal When Overexpressed in Yeast.
The
htop1T718A mutant, generated by site-directed mutagenesis,
was cloned into plasmid YCpGAL1-htop1T718A and transformed into EKY2
(top1
) cells. When cultured in galactose, cells
expressing htop1T718A exhibited a dramatic reduction in cell
viability (Fig. 3A). The cytotoxic
activity of hTop1T718Ap required catalytic activity, as mutation of the
active site Tyr723 to Phe abrogated htop1T718A-induced
lethality. Moreover, low constitutive levels of htop1T718A
expression from the yeast TOP1 promoter in YCpSc-htop1T718A was easily tolerated in EKY2 cells. In contrast, although JN2-134 cells transformed with YCpSc-hTOP1 were viable, no transformants were
obtained with YCpSc-htop1T718A. Low levels of hTop1T718Ap were
cytotoxic in rad52
, repair deficient strains (data not
shown). Thus, hTop1T718Ap-induced lethality was dependent upon cellular levels of mutant protein and the resultant DNA damage.
|
hTop1T718Ap Is Catalytically Active In Vitro and In Vivo.
As
shown in Fig. 3B, the specific activity of hTop1T718Ap was
indistinguishable from that of wild-type hTop1p. The in vivo activity
of hTop1p and hTop1T718Ap was assessed by examining the relaxation of
the positive supercoils generated by transcription of the endogenous
yeast 2-µm plasmid as described in Benedetti et al. (1993)
, Knab et
al. (1993)
, and Megonigal et al. (1997)
. JCW28 (top1
,
top2-4ts) cells, deleted for TOP1 and bearing a temperature-sensitive mutation in DNA topoisomerase II, were
cotransformed with YEptopA-pGPD and either YCpGAL1, YCpGAL1-hTOP1, or
YCpGAL1-htop1T718A. YEptopA-pGPD constitutively expresses bacterial DNA
Top1p. At 37°C, DNA topoisomerase II is inactivated and the negative
supercoils that accumulate during transcription are selectively relaxed
by bacterial DNA Top1p (Giaever and Wang, 1988
). As seen in Fig. 4A, JCW28 cells transformed with
YEptopA-pGPD and a control plasmid expressing no DNA Top1p accumulate
positively supercoiled (PS) 2-µm plasmid DNA upon shift to the
nonpermissive temperature (37°C). When JCW28 was transformed with
YCpGAL1-htop1T718A or YCpGAL1-hTOP1 and shifted to
nonpermissive temperature, the mutant or wild-type enzyme catalyzed the
relaxation of the positive supercoils (Fig. 4, B and C). Thus,
hTop1T718Ap is catalytically active in vivo.
|
Substitution of Ala for Thr718 in hTop1p Enhances Stability of
Covalent Enzyme-DNA Intermediate.
To assess the phenotypic
consequences of htop1T718A expression, the stability of the
covalent complex formed by the mutant enzyme was assessed. Equal
concentrations of heTop1 and heTop1T718A proteins, epitope tagged at
the N terminus, were bound to beads via the epitope specific M2
monoclonal antibody as described in Hann et al. (1998)
. The inclusion
of the epitope had no effect on mutant or wild-type enzyme activity,
either in solution or in the bead bound form (data not shown). The
tethered proteins were incubated with a 3' end-labeled DNA fragment, in
the presence or absence of 100 µM Cpt. Following incubation at 37°C
for 1, 5, or 30 min, the cleavable complexes were trapped with
SDS/proteinase K treatment and the cleaved DNA fragments resolved in a
denaturing polyacrylamide gel. When wild-type heTop1p is incubated
without Cpt, very little cleavage of the labeled DNA strand was
detected (Fig. 5). However, when heTop1p
is exposed to Cpt, a dramatic increase in cleaved DNA fragments was
observed. In contrast, heTop1T718Ap-DNA complexes were stabilized even
in the absence of Cpt, as evidenced by the increased intensity of
cleaved fragments relative to heTop1p (Fig. 5). Yet, the apparent
differences in band intensities produced in the presence and absence of
Cpt (compare heTop1T718Ap lanes with Cpt and DMSO) indicate that
heTop1T718Ap remains sensitive to Cpt. Moreover, because the pattern of
bands was indistinguishable between heTop1T718Ap and heTop1p in the
presence of Cpt, the preferred sites of cleavage by heTop1T718Ap are
altered by the drug (see arrow in Fig. 5, A and C). Band (B)
corresponds to the preferred cleavage site derived from rDNA (Bonven et
al., 1985
).
|
strains expressing hTOP1 or hTop1T718A was
examined 6 h after galactose induction (Fig.
6). There was a striking difference in
the distribution of nuclear DNA in the large-budded, G2/M
phase cells. In cells expressing hTOP1, >70% of the
large-budded cells had segregated the replicated nuclei into mother and
daughter cells and had two distinct nuclear masses. In contrast, cells
expressing hTop1T718A exhibited a marked derangement in
nuclear segregation; 65% of the large-budded cells contain a single
nucleus, either in the mother cell or in the bud neck between mother
and daughter cells.
|
Gly363 Substitutions Are Distinguished in Their Ability to Suppress
Cytotoxic Activity of hTop1T718A.
As detailed in Hann et al.
(1998)
, random mutagenesis identified a Gly295 to Val substitution as
an intragenic suppressor of ytop1T722A-induced lethality.
This resulted from a dramatic decrease in DNA binding and, therefore,
the catalytic activity of the double mutant. In contrast, our results
demonstrate that the same substitution (Gly363 to Val) in hTop1p had
only a minimal effect on enzyme activity, yet suppressed the Cpt
sensitivity of the human enzyme. To investigate whether the
interactions between the "lip" domain and the active-site tyrosine
residues differ in the yeast and human enzymes, the ability of all
three Gly363 substituents to suppress htop1T718A-induced
lethality was assessed.
|
, rad52
strain,
JN2-134. Galactose-induced mutant hTop1p expression was cytotoxic to
this repair-deficient strain, suggesting a critical level of DNA damage was induced by each double mutant.
The specific activities of the mutant proteins also were determined in
plasmid DNA relaxation assays. As shown in Fig. 7B, the ability of the
various Gly363 substituents to suppress the lethal activity of
hTop1T718Ap correlated with a reduction in catalytic activity. The
strongest suppressor, hTop1T718A, G363Vp exhibited the least catalytic
activity. The activity retained by hTop1T718A, G363Sp and hTop1T718A,
G363Cp was sufficient to render the enzyme sensitive to Cpt in vitro.
Assays of specific activity with increasing salt further demonstrate
that hTop1T718A, G363V was more sensitive to alterations in ionic
strength than hTop1p, hTop1T718A, G363Sp, or hTop1T718A, G363Cp because
its activity was impaired at salt concentrations in excess of 100 mM
(Fig. 7C). These data suggest that the combination of Gly363 to Val
with Thr718 to Ala compromises the catalytic activity of the enzyme,
possibly through a reduction in DNA binding.
Time course assays (Hertzberg et al., 1989
|
Molecular Modeling Analysis of Mutations.
Molecular
simulations were based on the coordinates of the three-dimensional
structure of hTop1p (70 kDa) in noncovalent complex with a 22-base pair
DNA duplex (Stewart et al., 1998
). The complete structure was
energy-minimized, after addition of the hydrogens, with the conjugate
gradients algorithm and AMBER forcefield. Individual substitutions,
T718A, G363C, G363S, and G363V, and double combinations were introduced
and the structures were again minimized for all residues within a 20-Å
radius from each mutation.
|
| |
Discussion |
|---|
|
|
|---|
Genetic, biochemical, and crystallographic studies contribute to
our current understanding of eukaryotic DNA Top1p structure and
mechanism (Lue et al., 1995
; Wang, 1996
; Berger, 1998
; Pommier et al.,
1998
; Redinbo et al., 1998
; Stewart et al., 1998
). Recent crystallographic data (Redinbo et al., 1998
; Stewart et al., 1998
) reveal that the enzyme forms a protein clamp around the DNA with basic
residues in contact with the phosphate backbone and the active site
tyrosine poised to attack the phosphodiester linkage. Stewart et al.
(1998)
proposed that the enzyme catalyzes the relaxation of supercoiled
DNA via a mechanism of "controlled rotation" in which the protein
clamp binds the DNA helix to create the single-stranded break. The DNA
molecule 3' to the cleavage site rotates about the phosphodiester bond
opposite the nick, with the positively charged surfaces of the
"linker region" (a coiled-coil structure that connects the central
globular core of the enzyme with the active site-tyrosine domain) and a
set of cone helices extending from the top of the clamp, acting as a
brake to slow the rotation of the negatively charged DNA. Specific
contacts with the DNA involve several Top1p domains. The residues of
the Cpt loop/lip region of core subdomain I also are involved in
interdomainal interactions with the lip region of core subdomain III
and in directly binding the DNA helix to form the closed clamp structure.
Among the Cpt-resistant mutants isolated in this screen, substitution
of Ala653 with Pro is interesting given its location in the coiled-coil
region of the linker domain. This mutant has reduced catalytic activity
(data not shown) and is particularly sensitive to proteolysis.
Substitution of Pro for Ala could disrupt the alpha helix of the
coiled-coil, thereby affecting the interaction of the enzyme with DNA.
Although the linker domain is dispensable for relaxation activity
(Stewart et al., 1997
), the presence of a modified structure could
alter the controlled rotation of DNA and influence the relaxation
activity of the enzyme.
Cpt resistance was previously ascribed to mutations in the Cpt loop/lip
region of core subdomain I (Benedetti et al., 1993
; Rubin et al., 1994
;
Lue et al., 1995
; Li et al., 1997
). Herein, we report that
substitution of Val or Ser for Gly363 had little effect on catalytic
activity, yet decreased the Cpt sensitivity of the enzyme to levels
similar to those observed with the Cpt-resistant htop1G363C mutant.
Subtle differences highlight the strict structural context required for
Cpt sensitivity and presumably drug binding. Our molecular models
suggest that substitutions in this lip region could affect enzyme
activity and sensitivity to Cpt by altering the conformation of the
loop. Arg364, which makes direct contact with the minor groove of the
DNA opposite the site cleaved by the active site tyrosine (Redinbo et
al., 1998
) is slightly distorted in the minimized structures, with the
G363C mutation being most pronounced. This distortion may influence the
hydrogen bonding with Cpt as proposed by Redinbo et al. (1998)
or might
affect the overall structure of the loop important for Cpt binding. In addition, as a single salt bridge exists between the two lip domains, any alteration in the correct positioning of these two regions might
adversely affect the interdomainal interactions needed to effect clamp
closure. The opening and closing of the enzyme clamp around the DNA
also could influence the Cpt binding-equilibrium. If hTop1p mutations
alter the efficiency of clamp closure, the equilibrium would shift
toward the unbound state.
Fan et al. (1998)
recently proposed an alternate model for Cpt binding,
based on molecular-modeling studies of different Cpt analogs and DNA.
Substitution of Ala for Thr718 produces different patterns of DNA
cleavage in the presence or absence of Cpt. In the presence of Cpt,
however, the pattern was indistinguishable between hTop1T718Ap and
hTop1p. Similar results were obtained with yTop1T722Ap (Megonigal et
al., 1997
), suggesting that Cpt binding to the mutant enzyme-DNA
complex restores the microenvironment around the active site. This is
in agreement with the Fan et al. (1998)
model.
Mutation of Gly363 to Val provided the strongest suppression of htop1T718A lethality. The molecular models suggest the introduction of the branched side chain of Val, as opposed to the smaller, linear side chains of Cys or Ser, produces a more severe alteration in the Cpt loop. This was reflected in a pronounced decrease in catalytic activity, but only in the context of the Thr718-to-Ala substitution. Thus, the flexibility imparted to the Cpt loop by Gly363 may be more critical in maintaining the altered catalytic activity of hTop1T718Ap than wild-type hTop1p. Indeed, substitution of Val, Ser, or Cys for Gly363 had comparable effects on wild-type enzyme activity and Cpt sensitivity: a modest decrease in activity at higher salt and resistance to Cpt.
The results of Gly363 substitutions in hTop1p differed from that
obtained following the substitution of Val for the corresponding residue (Gly295) in yTop1p, where a 100-fold decrease in yTop1G295Vp was attributed to a reduction in DNA binding (Hann et al., 1998b
). Yet,
consistent with the results presented herein, this effect was
exacerbated in the context of the lethal Thr to Ala substitution. Thus,
interactions of the Cpt loop/lip region with residues near the active
site tyrosine affect the catalytic activity of both yTop1p and hTop1p.
Alterations in the catalytic activity of hTop1p imparted by the Thr718
to Ala mutation mirror those reported for yTop1T722Ap (Megonigal et
al., 1997
). The DNA relaxation activity of hTop1T718Ap was essentially
identical with that of the wild-type enzyme. Furthermore, hTop1T718Ap
mimics the cytotoxic effects of Cpt. Wild-type and mutant enzyme
sensitivity to Cpt are comparable with regards to the degree and site
specificity of DNA cleavage. Yet, in the absence of Cpt, hTop1T718Ap
formed elevated levels of cleavable complexes. Therefore, either
treatment with Cpt or mutation of Thr718 to Ala enhances the stability
of the covalent enzyme-DNA intermediate. It is possible that different
steps in the catalytic cycle are affected, which would not be
distinguished by the assays used. Indeed, differences in the DNA
cleavage patterns created by hTop1T718Ap in the presence or absence of
Cpt support the hypothesis that the Thr718-to-Ala mutation and Cpt
treatment interfere with distinct aspects of the catalytic cycle.
Yeast and hTop1p share a high degree of similarity in terms of
sequence, structure, and enzyme mechanism. Moreover, the human enzyme
functions in yeast (Bjornsti et al., 1989
) and the yeast enzyme
functions in mammalian cells (Hann et al., 1998
). Yet, despite the
overwhelming similarities in enzyme structure and function, significant
differences have been reported (Merino et al., 1993
; Knab et al., 1995
;
Reid et al., 1997
). For example, yTop1p could not substitute for hTop1p
in suppressing the basal level of transcription in vitro. Because
hTop1p catalytic activity was not required, this implied a critical
difference in structure between enzymes. In these studies, mutation of
most conserved residues elicited similar alterations in enzyme
activity, yet significant differences were apparent. As numerous Cpt
analogs and other Top1p inhibitors are being developed as
chemotherapeutic agents, deciphering the structural features of Top1p
critical for Cpt sensitivity is important.
| |
Acknowledgments |
|---|
We thank Drs. James C. Wang, James M. Berger, David J. Hall, and M. Irene Baldi for helpful discussion; Drs. Paola Carlucci and Sandra Cicuzza for some help in the experiments; and Giuseppe Di Franco for excellent technical assistance.
| |
Footnotes |
|---|
Received November 16, 1998; Accepted August 13, 1999
1 Current Address: Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105.
2 Current Address: Division of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115.
This work was supported by a grant from Associazione Italiana per la Ricerca sul Cancro (to P.B.) and by National Institutes of Health Grant CA70406 (to M.-A.B.). P.F and A.S. were supported by fellowships from Fondazione A. Buzzati-Traverso and J.F.A. by a Yamagiwa-Yoshida fellowship from International Union Against Cancer.
Send reprint requests to: Dr. Piero Benedetti, Istituto di Biologia Cellulare, "Campus Adriano Buzzati-Traverso" Consiglio Nazionale delle Ricerche, via Ramarini 32, Monterotonda 00016, Rome, Italy. E-mail: pbenedetti{at}ibc.rm.cnr.it
| |
Abbreviations |
|---|
Top1p, DNA topoisomerase I; yTop1p, yeast DNA topoisomerase I protein; hTop1p, human DNA topoisomerase I protein; Cpt, camptothecin; DMSO, dimethyl sulfoxide.
| |
References |
|---|
|
|
|---|
Crystallographic structure and mechanistic implications.
Structure
3:
1315-1322[Medline].This article has been cited by other articles:
![]() |
G. Chillemi, I. D'Annessa, P. Fiorani, C. Losasso, P. Benedetti, and A. Desideri Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations Nucleic Acids Res., September 2, 2008; (2008) gkn558v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. van der Merwe and M.-A. Bjornsti Mutation of Gly721 Alters DNA Topoisomerase I Active Site Architecture and Sensitivity to Camptothecin J. Biol. Chem., February 8, 2008; 283(6): 3305 - 3315. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Losasso, E. Cretaio, K. Palle, L. Pattarello, M.-A. Bjornsti, and P. Benedetti Alterations in Linker Flexibility Suppress DNA Topoisomerase I Mutant-induced Cell Lethality J. Biol. Chem., March 30, 2007; 282(13): 9855 - 9864. [Abstract] [Full Text] [PDF] |
||||